NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free VCNX Stock Alerts $6.05 -0.13 (-2.10%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$6.01▼$6.5950-Day Range$4.76▼$8.8052-Week Range$4.43▼$100.80Volume2,740 shsAverage Volume9,826 shsMarket Capitalization$7.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaccinex alerts: Email Address Ad AltimetryStock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.Click here to learn what's coming (and how to prepare). About Vaccinex Stock (NASDAQ:VCNX)Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.Read More VCNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCNX Stock News HeadlinesApril 28, 2024 | americanbankingnews.comShort Interest in Vaccinex, Inc. (NASDAQ:VCNX) Increases By 157.1%April 14, 2024 | investing.comVaccinex faces Nasdaq compliance challengeMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.April 2, 2024 | investorplace.comVCNX Stock Earnings: Vaccinex Reported Results for Q4 2023April 2, 2024 | globenewswire.comVaccinex Reports 2023 Financial Results and Provides Corporate UpdateMarch 27, 2024 | globenewswire.comVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 6, 2024 | investing.comVaccinex CFO Scott Royer to retire, Jill Sanchez steps inMarch 2, 2024 | morningstar.comVaccinex Inc VCNXMay 5, 2024 | Altimetry (Ad)Stock-Picking AI Predicts #1 Stock of 2024Since the start of the year, the top 10 investment funds in the world – including Vanguard, Blackrock, Fidelity and JP Morgan – have made nearly $1 trillion in profits on these 7 stocks.February 21, 2024 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus TechnologyFebruary 21, 2024 | markets.businessinsider.comVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery PlatformFebruary 21, 2024 | finance.yahoo.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 21, 2024 | globenewswire.comVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyFebruary 15, 2024 | markets.businessinsider.comVaccinex Announces 1-For-14 Reverse Stock SplitFebruary 15, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Trading LowerFebruary 15, 2024 | globenewswire.comVaccinex, Inc. Announces Reverse Stock SplitFebruary 12, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex IncFebruary 8, 2024 | msn.comVaccinex Inc Secures $3.7M in Private Placement DealFebruary 7, 2024 | msn.comWhy Vaccinex (VCNX) Stock Is Popping OffFebruary 7, 2024 | markets.businessinsider.comVaccinex Announces Pricing of $3.7 Million PIPE FinancingDecember 4, 2023 | finance.yahoo.comNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing RuleNovember 13, 2023 | finance.yahoo.comVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 31, 2023 | finance.yahoo.comVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingOctober 26, 2023 | finance.yahoo.comVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative DiseasesOctober 6, 2023 | markets.businessinsider.comWhy Is Vaccinex (VCNX) Stock Up 26% Today?September 29, 2023 | finanznachrichten.deVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public OfferingSeptember 29, 2023 | marketwatch.comVaccinex Shares Slide Premarket After Stock OfferingSee More Headlines Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/02/2024Today5/05/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VCNX CUSIPN/A CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees37Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($100.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,250,000.00 Net MarginsN/A Pretax Margin-3,552.81% Return on Equity-2,667.31% Return on Assets-571.70% Debt Debt-to-Equity RatioN/A Current Ratio0.57 Quick Ratio0.57 Sales & Book Value Annual Sales$570,000.00 Price / Sales13.08 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-2.34Miscellaneous Outstanding Shares1,232,000Free Float598,000Market Cap$7.45 million OptionableOptionable Beta0.74 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Maurice Zauderer Ph.D. (Age 77)Co-Founder, CEO, President & Director Comp: $411.7kDr. Elizabeth E. Evans Ph.D. (Age 51)COO and Senior VP of Discovery & Translational Medicine Comp: $291.57kDr. Ernest S. Smith Ph.D. (Age 52)Senior VP of Research & Chief Scientific Officer Comp: $297.25kMs. Jill Sanchez CPA (Age 52)Chief Financial Officer Dr. John E. Leonard Ph.D. (Age 77)Senior Vice President of Development Key CompetitorsCan-Fite BioPharmaNYSE:CANFTrevenaNASDAQ:TRVNPasithea TherapeuticsNASDAQ:KTTAHepion PharmaceuticalsNASDAQ:HEPAAyala PharmaceuticalsNASDAQ:ADXSView All CompetitorsInsiders & InstitutionsAlbert FriedbergBought 282 shares on 4/19/2024Total: $1,333.86 ($4.73/share)AIGH Capital Management LLCSold 273,112 shares on 2/12/2024Ownership: 6.542%Worth Venture Partners LLCSold 63,480 shares on 2/9/2024Ownership: 5.237%Strydonck Gerald E. VanSold 224 sharesTotal: $2,257.92 ($10.08/share)Albert FriedbergBought 214,285 shares on 10/3/2023Total: $3.00 M ($14.00/share)View All Insider TransactionsView All Institutional Transactions VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed in 2024? Vaccinex's stock was trading at $9.3072 at the start of the year. Since then, VCNX stock has decreased by 35.0% and is now trading at $6.05. View the best growth stocks for 2024 here. Are investors shorting Vaccinex? Vaccinex saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 16,200 shares, an increase of 157.1% from the March 31st total of 6,300 shares. Based on an average daily volume of 13,200 shares, the short-interest ratio is currently 1.2 days. Approximately 3.0% of the shares of the stock are short sold. View Vaccinex's Short Interest. When is Vaccinex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our VCNX earnings forecast. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings results on Tuesday, April, 2nd. The company reported ($39.40) earnings per share (EPS) for the quarter. When did Vaccinex's stock split? Shares of Vaccinex reverse split on the morning of Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX). When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VCNX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsCharles Payne Demystifies OptionsUnstoppable ProsperityAutomatic Income (from home)Awesomely, LLCThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.